Cargando…

Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma

PURPOSE: The study aimed to investigate the potential benefit of more than 4 courses of S1 adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma (PDAC) after surgery. METHOD: Data were retrospectively collected from consecutive patients who underwent S-1 adjuvant chemotherapy foll...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Bo, Shen, Shuo, You, Siting, Zhang, Guoxiao, Gao, Suizhi, Shi, Xiaohan, Wang, Huan, Yin, Xiaoyi, Xu, Xiongfei, Guo, Shiwei, Jin, Gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152347/ https://www.ncbi.nlm.nih.gov/pubmed/34034684 http://dx.doi.org/10.1186/s12885-021-08380-9

Ejemplares similares

A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma
por: Zhu, Lingyu, et al.
Publicado: (2023)

Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA
por: Wu, Huanwen, et al.
Publicado: (2022)

Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients
por: Guo, Shiwei, et al.
Publicado: (2020)

Modified artery-first approach for distal pancreatectomy with celiac axis resection
por: Wang, Huan, et al.
Publicado: (2023)

Pros and Cons: High Proportion of Stromal Component Indicates Better Prognosis in Patients With Pancreatic Ductal Adenocarcinoma—A Research Based on the Evaluation of Whole-Mount Histological Slides
por: Li, Bo, et al.
Publicado: (2020)

Nomogram for the Prediction of High-Grade Dysplasia and Invasive Carcinoma in Patients With Intraductal Papillary Mucinous Neoplasms of the Pancreas Based on Variables of Noninvasive Examination
por: Li, Bo, et al.
Publicado: (2021)

Relationship Between Radiomics and Risk of Lymph Node Metastasis in Pancreatic Ductal Adenocarcinoma
por: Bian, Yun, et al.
Publicado: (2019)

Radiomics nomogram for the preoperative prediction of lymph node metastasis in pancreatic ductal adenocarcinoma
por: Bian, Yun, et al.
Publicado: (2022)

The Landscape of Genetic Alterations Stratified Prognosis in Oriental Pancreatic Cancer Patients
por: Guo, Shiwei, et al.
Publicado: (2021)

Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data
por: Chikhladze, Sophia, et al.
Publicado: (2019)

An EMT-Related Gene Signature for Predicting Response to Adjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma
por: Feng, Zengyu, et al.
Publicado: (2021)

Blood small extracellular vesicles derived miRNAs to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis
por: Guo, Shiwei, et al.
Publicado: (2021)

Morphomolecular staging to improve stratification of patients with node-negative pancreatic cancer
por: Shi, Xiaohan, et al.
Publicado: (2023)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
por: de Jong, Evelien J. M., et al.
Publicado: (2021)

Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy
por: Mortier, Victor, et al.
Publicado: (2022)

Comparison of adjuvant gemcitabine plus S-1 with S-1 monotherapy for pancreatic ductal adenocarcinoma: Retrospective real-world data
por: Tang, Hui, et al.
Publicado: (2022)

Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate‐adjusted analysis at the pre‐adjuvant chemotherapy timing
por: Fu, Ningzhen, et al.
Publicado: (2022)

Clarifying the role of adjuvant therapy after multi-agent neoadjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma
por: Lan, Xiaoyang, et al.
Publicado: (2023)

Adjuvant Chemotherapy and Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma: A Systematic Review and Clinical Practice Guideline
por: Biagi, James J., et al.
Publicado: (2023)

The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma
por: Ma, Heng, et al.
Publicado: (2023)

Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX
por: Lee, So Heun, et al.
Publicado: (2023)

Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma
por: Wysocka, Olga, et al.
Publicado: (2016)

Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
por: Klein-Brill, Avital, et al.
Publicado: (2022)

Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study
por: Kamarajah, Sivesh K., et al.
Publicado: (2021)

Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
por: Zong, Yuan, et al.
Publicado: (2020)

Expression of LMO4 and outcome in pancreatic ductal adenocarcinoma
por: Murphy, N C, et al.
Publicado: (2008)

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
por: Ei, Shigenori, et al.
Publicado: (2023)

Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: a retrospective cohort study
por: Pu, Ning, et al.
Publicado: (2023)

Pancreatic ductal adenocarcinoma: Role of chemotherapy & future perspectives
por: Tiwari, Akash, et al.
Publicado: (2018)

SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma
por: Fei, Naomi, et al.
Publicado: (2021)

An unusual genomic variant of pancreatic ductal adenocarcinoma with an indolent clinical course
por: Kohutek, Zachary A., et al.
Publicado: (2017)

Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1)
por: Gao, Suizhi, et al.
Publicado: (2019)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
por: Rogers, Jane E., et al.
Publicado: (2020)

The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma—including the analysis of clinicopathological factors influencing relative dose intensity
por: Yabusaki, Norimitsu, et al.
Publicado: (2016)

Which is the optimal adjuvant chemotherapy for resected pancreatic ductal adenocarcinoma?: A protocol for a network meta-analysis of randomized controlled trials
por: Hu, Qiancheng, et al.
Publicado: (2019)

SMAD4 and the TGFβ Pathway in Patients with Pancreatic Ductal Adenocarcinoma
por: Dardare, Julie, et al.
Publicado: (2020)

Systematic Characterization of the Clinical Relevance of KPNA4 in Pancreatic Ductal Adenocarcinoma
por: Bao, Jingpiao, et al.
Publicado: (2022)

GATA4 Regulates Inflammation-Driven Pancreatic Ductal Adenocarcinoma Progression
por: Jiang, Weiliang, et al.
Publicado: (2021)

KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab
por: Chiari, Rita, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lhr86td551smiuhn6so6op9oa2